News
WeNatal donates over $25,000 worth of products to those affected by LA wildfires

The co-founder of fertility-focused supplement brand, WeNatal, has donated over $25,000 worth of products to her community after losing her own home in LA’s wildfires.
Former Nike executive and WeNatal co-founder, Ronit Menashe, saw her family home in the Palisades destroyed during the fires which devastated Los Angeles earlier this month.
Celebrity nutritionist, Brigid Titgemeier, who was staying with the family at the time, shared an Instagram post documenting the events that took place after a fire broke out next to Menashe’s daughter’s pre-school.
They rushed home to pack their belongings before evacuating, with another photo— thought to be from a few hours later—showing their town ‘burned to the ground’.

Instagram/Brigid Titgemeier
The following day, Menashe posted on Instagram offering to send free supplements to those in her community who had also ‘lost everything’.
“This is the person that she is,” Titgemeier wrote in an accompanying caption.
“After losing everything she still wants to help others.”

Instagram/Brigid Titgemeier
Menashe reached out to those in her neighbourhood and community group chats, and individually texted friends and customers who she knew were pregnant. She also advised others on how the supplements could be taken as a multivitamin to support their overall wellbeing.
“I couldn’t stop thinking about the families, especially pregnant women, who were also going through this trauma,” Menashe told Femtech World.
“While it is incredibly easy to slip into feelings of overwhelm and helplessness at this time, in all circumstances of loss, it’s critical to focus on what we can do.
“A natural way I could give back to my community, which lost everything, was to offer them a way to support their health—no one was sleeping or eating, and it’s so easy to neglect your health during times like this. But these are precisely the moments when focusing on nutrition should be a top priority.”

Instagram/Brigid Titgemeier
The WeNatal team has now sent out over $25,000 worth of products to help women and their look after their health in the aftermath.
She continued: “No doubt rebuilding will be challenging for us all, but I’ve been so moved by how so many have shown up in meaningful ways, and it is this strong sense of community and generosity that will bring us to the other side.”
A ‘new sense of hope’
Menashe founded WeNatal with her former Nike colleague, Vida Delrahim, after they both experienced miscarriages just a week apart.
One in six couples experience infertility, with up to half of these cases attributed to male factors. But Menashe and Delrahim say their partners were ‘left out of the discussion’.
The brand, which aims to support fertility in both men and women, has been backed by high-profile functional medicine practitioners, such as Dr Mark Hyman and Kelly LeVeque.
“This isn’t the first time we’ve been compelled to give after a loss,” said Menashe.
“Our brand started after my co-founder Vida and I both had miscarriages a week apart. We were sad for ourselves, yes, but also for all the couples like us who were given little direction on what to do differently to improve our fertility.
She added: “Beyond products, our deep hope and the focus of so many of our educational and community-building efforts is to foster a new sense of hope.”
Fertility
Housing, work and fertility stop Britons having the families they want – research
Fertility
Femtech World reveals fertility innovation award shortlist

Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist

HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care

Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.

Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
Cancer
Common cholesterol drug shows ovarian cancer promise

A common cholesterol drug could help weaken a fluid shield that helps ovarian cancer tumours survive, early lab findings suggest.
The findings do not show the drug treats ovarian cancer. But they suggest changing the environment the cancer depends on could make it more vulnerable to existing treatment.
A federally funded study at Duke University School of Medicine found that ascites, a build-up of fluid in the abdomen, may do more than cause discomfort.
Doctors can drain ascites to ease pain, improve mobility and make breathing easier, but the fluid may also help cancer cells survive and spread. It occurs in 90 per cent of people with advanced ovarian cancer.
According to the study, ascites acts as a shield, helping cancer cells evade ferroptosis, a form of cell death.
Ferroptosis is a kind of cellular rusting. It happens when iron inside a cell reacts with certain fats, causing the cell membrane to break apart.
Many metastatic cancer cells, meaning cells that float freely through the abdomen looking for new places to grow, are naturally vulnerable to this kind of damage.
“Doctors have mostly viewed ascites as a symptom rather than an active driver of disease,” said Jen-Tsan Chi, professor in the department of molecular genetics and microbiology and co-leader of the Cancer Biology Program at the Duke Cancer Institute.
“We’ve learned it gives cancer a survival advantage, which fills a major gap in understanding how ovarian cancer spreads.”
Scientists bathed cancer cell lines and patient-derived tumour cells in ascites collected from patients and watched how they responded to ferroptosis triggers.
The fluid protected cancer cells by changing how they store fats and control iron levels, effectively blocking cell death.
The protection required only trace amounts, with as little as 2 per cent immersion shielding cancer cells from destruction.
“What surprised us was how selective this effect was,” said Yasaman Setayeshpour, first author and graduate student in molecular genetics and microbiology at Duke School of Medicine.
“Ascites didn’t protect the cancer cells from other well-known types of cell death, like apoptosis or necrosis, it only blocked ferroptosis.
“To figure out why, we broke ascites down into major parts, like lipids, proteins, and small molecules, and tested what happened when each was removed.
“When we took the lipids out, the protective effect disappeared. That told us lipids are the key reason ascites helps these cancer cells survive.”
But researchers found an unexpected helper in bezafibrate, an older cholesterol drug used to lower triglycerides by altering how the body processes fats.
The cholesterol drug restored sensitivity to ferroptosis, but only when ascites was present. On its own, the drug did not trigger cell death or slow tumour growth in mice.
The drug’s impact depended on the cancer’s surroundings, in this case the fat-rich fluid bathing the tumour. Researchers found that targeting this environment, using repurposed drugs like bezafibrate, could leave cancer cells more exposed to existing cancer treatments.
Chi said the finding could have implications beyond ovarian cancer. Other cancers, including colorectal and pancreatic cancers, can also spread within the abdominal cavity.
“This work shows how much the environment around a tumour matters,” Chi said.
“Biological fluids like ascites don’t just give cancer cells a place to move. They actively help drive how cancer spreads.”
Entrepreneur3 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur2 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis3 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Fertility4 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause4 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health3 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Wellness3 weeks agoResistance training has preventative effects in menopause, study finds
Entrepreneur4 weeks agoFlora Fertility closes US$5m seed round












